Sam Samad net worth and biography

Sam Samad Biography and Net Worth

CFO of Illumina

Sam Samad joined Illumina in 2017 and holds the role of Chief Financial Officer with responsibility for the company’s finance, accounting, investor relations, internal audit, treasury, and global information systems functions.

Before joining Illumina, Samad held several senior leadership positions at Cardinal Health including Senior Vice President and Corporate Treasurer, leading all tax and treasury functions. During his tenure as Treasurer, Samad also had operational and financial responsibility for Cardinal Health’s China business. Prior to that, Samad served as Senior Vice President and Chief Financial Officer for Cardinal Health’s $85B pharmaceutical segment, among other leadership roles. Prior to Cardinal Health, Samad spent thirteen years at Eli Lilly and Company, in a variety of sales and finance roles, both domestically and internationally, including his role as Chief Financial Officer of the Canada affiliate prior to leaving Eli Lilly. Samad started his career at Pepsico Inc.

Samad has served as Director on the Board for IDEXX Laboratories, Inc. (IDXX) since July 2019 and on the Board of Visitors at the Owen Graduate School of Management since 2016.

Samad holds a BBA degree from the American University of Beirut in Lebanon and an MBA from McMaster University in Hamilton, Canada.

What is Sam Samad's net worth?

The estimated net worth of Sam Samad is at least $848,570.04 as of May 26th, 2020. Mr. Samad owns 3,879 shares of Illumina stock worth more than $848,570 as of December 3rd. This net worth evaluation does not reflect any other assets that Mr. Samad may own. Learn More about Sam Samad's net worth.

How do I contact Sam Samad?

The corporate mailing address for Mr. Samad and other Illumina executives is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. Illumina can also be reached via phone at (858) 202-4500 and via email at [email protected] Learn More on Sam Samad's contact information.

Has Sam Samad been buying or selling shares of Illumina?

Sam Samad has not been actively trading shares of Illumina in the last ninety days. Most recently, Sam Samad sold 1,356 shares of the business's stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $360.00, for a transaction totalling $488,160.00. Following the completion of the sale, the chief financial officer now directly owns 3,879 shares of the company's stock, valued at $1,396,440. Learn More on Sam Samad's trading history.

Who are Illumina's active insiders?

Illumina's insider roster includes Alexander Aravanis (SVP), Frances Arnold (Director), Charles Dadswell (SVP), Francis deSouza (CEO), Phillip Febbo (SVP), Jay Flatley (Director), Aimee Hoyt (SVP), Karen Mcginnis (CAO), Robert Ragusa (SVP), Mostafa Ronaghi (SVP), Sam Samad (CFO), Susan Tousi (SVP), and Mark Van Oene (SVP). Learn More on Illumina's active insiders.

Are insiders buying or selling shares of Illumina?

In the last year, insiders at the life sciences company sold shares 12 times. They sold a total of 8,309 shares worth more than $2,739,762.78. The most recent insider tranaction occured on November, 7th when SVP Susan H Tousi sold 500 shares worth more than $111,825.00. Insiders at Illumina own 0.1 % of the company. Learn More about insider trades at Illumina.

Information on this page was last updated on 11/7/2022.

Sam Samad Insider Trading History at Illumina

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/26/2020Sell1,356$360.00$488,160.003,879View SEC Filing Icon  
5/18/2020Sell1,357$340.00$461,380.005,235View SEC Filing Icon  
4/20/2020Sell1,356$320.02$433,947.126,592View SEC Filing Icon  
4/16/2020Sell1,697$300.00$509,100.007,948View SEC Filing Icon  
4/14/2020Sell249$292.54$72,842.469,645View SEC Filing Icon  
11/29/2019Sell892$320.00$285,440.003,461View SEC Filing Icon  
See Full Table

Sam Samad Buying and Selling Activity at Illumina

This chart shows Sam Samad's buying and selling at Illumina by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Illumina Company Overview

Illumina logo
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
Read More

Today's Range

Now: $218.76
Low: $211.00
High: $219.55

50 Day Range

MA: $214.81
Low: $184.12
High: $242.74

2 Week Range

Now: $218.76
Low: $173.45
High: $428.00

Volume

1,086,361 shs

Average Volume

1,326,745 shs

Market Capitalization

$34.41 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.14
Bear Market Expert Reveals His #1 Stock for November 2023 
"I went from the brink of bankruptcy to wealthy – thanks to one type of stock". Get his top pick here.
>>>
pixel